Aravind Palraj/LinkedIn
Jul 7, 2026, 22:23
Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
Aravind Palraj, Senior Resident in Clinical Immunology and Rheumatology at Madras Medical College, shared a post on X:
“Antiphospholipid Syndrome is not just ‘start warfarin and follow INR.’
Management depends on:
- Thrombosis type (arterial vs venous)
- Obstetric profile
- Antibody pattern (triple-positive risk)
- Recurrent events
Triple-positive APS – Avoid DOACs Recurrent arterial events – Consider higher INR target Catastrophic APS – Anticoagulation plus steroids plus PLEX plus IVIG APS care is risk-stratified medicine.”
Find more posts featuring Aravind Palraj on Hemostasis Today.
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE
-
Oct 12, 2026, 20:43Jazlyn A Selvasingh: Excited to Share Our Research at AAO-HNSF 2026 in Los Angeles
-
Oct 12, 2026, 20:31Natalia Kovtun: Higher Ferritin Cutoffs Now Define Iron Deficiency
-
Oct 12, 2026, 19:39Edward Loftus: Using Low-Dose Aspirin in Pregnant Women With IBD
-
Oct 12, 2026, 19:32Shruti Sachdeva: Strengthening the Fight against Anemia